RnRMarketResearch.com adds “Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015” to its store. The report provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris)'s therapeutic pipeline.

Dallas, TX -- (SBWire) -- 07/21/2015 --Latest report, "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies mentioned in the report are Almirall, S.A. , Amgen Inc. , Avesthagen Limited , Avexxin AS , Biocon Limited , Biotie Therapies Corp., Can-Fite BioPharma Ltd., Celltrion, Inc. , Circassia Pharmaceuticals plc, Coherus BioSciences, Inc., Creabilis SA , Delenex Therapeutics AG, Dermira Inc. , Epirus Biopharmaceuticals, Inc., Forward Pharma A/S , Galectin Therapeutics, Inc., Genor BioPharma Co., Ltd., Idera Pharmaceuticals, Inc., Invion Limited , Johnson & Johnson , Kadmon Corporation, LLC, Kineta, Inc. , Kyowa Hakko Kirin Co., Ltd., LEO Pharma A/S , Lipidor AB, Mabion SA , Maruho Co., Ltd. , Momenta Pharmaceuticals, Inc., Oncobiologics, Inc. , Pfizer Inc. ,Promius Pharma, LLC , Protalix BioTherapeutics, Inc., Provectus Biopharmaceuticals, Inc., R-Tech Ueno, Ltd. , TetraLogic Pharmaceuticals, Therapeutic Proteins International, LLC, UCB S.A. , Valeant Pharmaceuticals International, Inc., XBiotech USA, Inc.

Complete report on Plaque Psoriasis (Psoriasis Vulgaris), spread across 235 pages is available at
http://www.rnrmarketresearch.com/plaque-psoriasis-psoriasis-vulgaris-pipeline-review-h1-2015-market-report.html

Scope

-The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Drugs profile mention in this report includes (betamethasone dipropionate + bexarotene), (calcipotriene + betamethasone dipropionate), (calcipotriene + betamethasone), adalimumab biosimilar, AM-001, ASKP-1240, AVX-001, betamethasone + maxacalcitol, bimekizumab, brodalumab, BTT-1023, calcipotriene, CF-101, CIR-001, CT-327, dalazatide, DFD-01, DFD-06, dimethyl fumarate, DLX-105, DRM-02, etanercept biosimilar, GK-664S, GR-MD-02, guselkumab, IDP-118, IMO-8400, infliximab biosimilar, INV-103, KD-025, LEO-32731, LP-0113, M-801801, MOL-4239, MOL-4249, pefcalcitol, PF-04965842, PF-06700841, PH-10, RA-18C3, RTU-1096, SHP-141, tofacitinib, toreforant, ustekinumab.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=395195
(This is a premium report priced at US$2000 for a single user License.)

Table of Contents
List of Tables
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2015 14
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Development by Companies, H1 2015 (Contd..3) 26
Products under Development by Companies, H1 2015 (Contd..4) 27
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H1 2015 28
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H1 2015 29
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avesthagen Limited, H1 2015 30
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H1 2015 31
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H1 2015 32
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biotie Therapies Corp., H1 2015 33
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H1 2015 34
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celltrion, Inc., H1 2015 35
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Circassia Pharmaceuticals plc, H1 2015 36
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H1 2015 37
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Creabilis SA, H1 2015 38
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Delenex Therapeutics AG, H1 2015 39
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Dermira Inc., H1 2015 40
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 41
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H1 2015 42
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Galectin Therapeutics, Inc., H1 2015 43
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co., Ltd., H1 2015 44
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 45
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Invion Limited, H1 2015 46
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H1 2015 47
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H1 2015 48
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kineta, Inc., H1 2015 49
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 50
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H1 2015 51
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H1 2015 52
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mabion SA, H1 2015 53
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H1 2015 54
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 55
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H1 2015 56
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H1 2015 57
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H1 2015 58
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H1 2015 59
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 60
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by R-Tech Ueno, Ltd., H1 2015 61
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TetraLogic Pharmaceuticals, H1 2015 62
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H1 2015 63
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H1 2015 64
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 65
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech USA, Inc., H1 2015 66
Assessment by Monotherapy Products, H1 2015 67
Assessment by Combination Products, H1 2015 68
Number of Products by Stage and Target, H1 2015 70
Number of Products by Stage and Mechanism of Action, H1 2015 73
Number of Products by Stage and Route of Administration, H1 2015 75
Number of Products by Stage and Molecule Type, H1 2015 77
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Recent Pipeline Updates, H1 2015 164
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H1 2015 220
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H1 2015 221
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H1 2015 222
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H1 2015 223
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H1 2015 224
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H1 2015 225
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H1 2015 226

Explore more reports on Dermatology therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.